A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Spartalizumab (Primary) ; WNT 974 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Novartis
- 22 Feb 2018 Planned End Date changed from 10 Jan 2020 to 9 Jan 2020.
- 22 Feb 2018 Planned primary completion date changed from 25 Sep 2018 to 9 Jan 2020.
- 24 Feb 2017 PDR-001 primary drug has been added hence treatment arms also increases from 1 to 2.